SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Amazon Explores AI Content Marketplace With Media Publishers 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
DURHAM, N.C., Feb. 22, 2018 -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that it will host a live conference call and audio webcast on Thursday, March 1, 2018 at 8:30 a.m. ET to report financial results for the fourth quarter and full year ended December 31, 2017, and to provide a business overview.
To access the live conference call, please dial (877) 354-4056 (domestic) or (678) 809-1043 (international) at least five minutes prior to the start time, and refer to conference ID 1153769. A live audio webcast of the call will also be available on the Investors’ section of the Company's website, www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology and Compound Library have produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and a new clinical candidate, CMX521, the first direct-acting antiviral specifically for the treatment and prevention of norovirus to enter clinical testing. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT:
Investor Relations:
Michelle LaSpaluto
919-972-7115
[email protected]
or
Will O’Connor
Stern Investor Relations
[email protected]
212-362-1200
Media:
Becky Vonsiatsky
W2O Group
[email protected]
413-478-2003
